Company news

Roivant Sciences Ltd. news in 2025

Roivant Sciences Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 10, 2025

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

November 9, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 27, 2025

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 26, 2025

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

September 16, 2025

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

September 10, 2025

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 4, 2025

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

September 2, 2025

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 10, 2025

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 27, 2025

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025

Roivant and Priovant to Host Investor Video Conference at 1: 00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 8, 2025

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 28, 2025

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

May 14, 2025

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

March 18, 2025

Roivant to Host Investor Webcast at 8: 00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

March 17, 2025

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board

February 24, 2025

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

February 9, 2025

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

January 28, 2025

Calls in 2025

Decks in 2025